Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amanda Clarke

Showing results (91-100 of 124) with videos related to

Pageof 13
Sort By:
HIV Research & Clinical Practice|July 16, 2019
Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in Asian participants with human immunodeficiency virus 1 infection: A sub-analysis of phase 3 clinical trialsYeon-Sook Kim, Shinichi Oka, Ploenchan Chetchotisakd, et al.
HIV Medicine|January 12, 2024
Clinical epidemiology of COVID-19 in people of black ethnicity living with HIV in the UKZoe Ottaway, Lucy Campbell, Laura R Cechin, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 2, 2016
Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 ResultsDavid Wohl, Shinichi Oka, Nathan Clumeck, et al.
AIDS and Behavior|October 12, 2018
The Context of Sexual Risk Behaviour Among Men Who Have Sex with Men Seeking PrEP, and the Impact of PrEP on Sexual BehaviourMitzy Gafos, Rob Horne, Will Nutland, et al.
Journal of Virus Eradication|October 6, 2021
No evidence of neuronal damage as measured by neurofilament light chain in a HIV cure study utilising a kick-and-kill approachJasmini Alagaratnam, Wolfgang Stöhr, Jamie Toombs, et al.
The Lancet Regional Health. Europe|July 22, 2024
All-cause and AIDS-related mortality among people with HIV across Europe from 2001 to 2020: impact of antiretroviral therapy, tuberculosis and regional differences in a multicentre cohort studyChristian Kraef, Erich Tusch, Sabine Singh, et al.
AIDS (London, England)|November 8, 2017
Where is the greatest impact of uncontrolled HIV infection on AIDS and non-AIDS events in HIV?Amanda Mocroft, Kamilla Laut, Peter Reiss, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 20, 2020
Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results From a Pan-European StudySarah Amele, Lars Peters, Alison Rodger, et al.
AIDS (London, England)|July 18, 2022
Changes in body mass index and clinical outcomes after initiation of contemporary antiretroviral regimensWendy P Bannister, T Christopher Mast, Stéphane de Wit, et al.
AIDS (London, England)|July 24, 2019
Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in EuropeBastian Neesgaard, Annegret Pelchen-Matthews, Lene Ryom, et al.
Pageof 13

Showing results (91-100 of 124) with videos related to

Sort By:
Pageof 13
HIV Research & Clinical Practice|July 16, 2019
Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in Asian participants with human immunodeficiency virus 1 infection: A sub-analysis of phase 3 clinical trialsYeon-Sook Kim, Shinichi Oka, Ploenchan Chetchotisakd, et al.
HIV Medicine|January 12, 2024
Clinical epidemiology of COVID-19 in people of black ethnicity living with HIV in the UKZoe Ottaway, Lucy Campbell, Laura R Cechin, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 2, 2016
Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 ResultsDavid Wohl, Shinichi Oka, Nathan Clumeck, et al.
AIDS and Behavior|October 12, 2018
The Context of Sexual Risk Behaviour Among Men Who Have Sex with Men Seeking PrEP, and the Impact of PrEP on Sexual BehaviourMitzy Gafos, Rob Horne, Will Nutland, et al.
Journal of Virus Eradication|October 6, 2021
No evidence of neuronal damage as measured by neurofilament light chain in a HIV cure study utilising a kick-and-kill approachJasmini Alagaratnam, Wolfgang Stöhr, Jamie Toombs, et al.
The Lancet Regional Health. Europe|July 22, 2024
All-cause and AIDS-related mortality among people with HIV across Europe from 2001 to 2020: impact of antiretroviral therapy, tuberculosis and regional differences in a multicentre cohort studyChristian Kraef, Erich Tusch, Sabine Singh, et al.
AIDS (London, England)|November 8, 2017
Where is the greatest impact of uncontrolled HIV infection on AIDS and non-AIDS events in HIV?Amanda Mocroft, Kamilla Laut, Peter Reiss, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 20, 2020
Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results From a Pan-European StudySarah Amele, Lars Peters, Alison Rodger, et al.
AIDS (London, England)|July 18, 2022
Changes in body mass index and clinical outcomes after initiation of contemporary antiretroviral regimensWendy P Bannister, T Christopher Mast, Stéphane de Wit, et al.
AIDS (London, England)|July 24, 2019
Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in EuropeBastian Neesgaard, Annegret Pelchen-Matthews, Lene Ryom, et al.
Pageof 13